Baby movement and oxygen monitors: what the evidence shows

2026-10-11

Movement, heart rate and oxygen monitors sold to parents promise to watch a baby through the night. The FDA safety communication of 16 September 2025 and the American Academy of Pediatrics are clear on one point: these devices detect, they do not prevent, and no monitor has been authorised to stop a sudden infant death. What is proved concerns the conditions a baby sleeps in.

What the monitors sold to parents promise

A monitor designed for a baby's sleep promises vigilance: it tracks movement, heart rate or blood oxygen and sounds an alarm when a reading drifts. Many are sold without a prescription, and the FDA safety communication of 16 September 2025 notes that such monitors often lack marketing authorisation, which means the agency has not assessed their safety or their effectiveness.

The FDA states that it knows of no clinical or scientific evidence that currently available baby products prevent or reduce the risk of sudden infant death syndrome. It goes further: no device, monitors included, has been authorised to prevent sudden infant death or sudden unexpected infant death, known as SUID.

The agency treats the claim itself carefully. On its page on baby products with SIDS prevention claims, the FDA explains that a product claiming to prevent sudden death becomes a medical device, and that it has authorised none for that purpose. Devices it has evaluated and cleared carry product code QYU, a marker worth checking when a seller advertises a monitor as medical.

The recommendation that settles it

The American Academy of Pediatrics published its updated safe sleep recommendations on 21 June 2022. Among them is a level A recommendation, the strongest the academy issues: home cardiorespiratory monitors should not be used as a strategy to reduce the risk of sudden infant death syndrome.

That recommendation rests on four large epidemiological studies conducted between 1986 and 2001. The academy also asks parents to avoid commercial devices that claim to reduce the risk, because there is no evidence they do. Its experts warn that these products can give a false sense of security and complacency.

France reached a comparable position earlier. The Haute Autorité de santé recommended in 2007 that the systematic use of self-monitoring devices or mattresses designed to detect apnoea and bradycardia no longer be used as in the past, a position relayed by Santé publique France on its page on sudden unexpected infant death. The French public health agency adds that this kind of death is the leading circumstance of death among infants under one year.

A monitor alerts, it does not protect

The distinction that matters is between detection and prevention. A monitor can flag a change in a reading and wake a parent, but the FDA says inaccurate readings can lead to unnecessary care, and neither it nor the AAP presents any of these devices as able to stop a death.

The AAP's warning is about the gap between the reassurance a device produces and the protection it provides. When a parent trusts an alarm to carry the night watch, the attention that safe sleep asks for can slip, which is the complacency the academy names. That is not a verdict on families who bought a monitor: the sources describe what a device can and cannot do, not what a parent should have done.

The FDA also draws a line on what a device replaces. Monitoring does not take the place of an adult nearby, and it does not take the place of the safe sleep rules. On its own, an alert during the night changes nothing about the conditions in which a baby sleeps.

What is established for the night

The strongest evidence points to a set of gestures, not to a gadget. The AAP technical report published in 2022 in Pediatrics recommends placing a baby on the back for every sleep, by every caregiver, until one year, and states that the side position is not safe and is not recommended.

The same report describes the sleep space: a firm, flat, non-inclined surface, and sharing the room without sharing the bed. HealthyChildren.org, the AAP's consumer site, repeats the rule on its 2022 page on safe sleep: a baby alone in their bed, on the back, without soft bedding, without soft objects and without an inclined surface.

One common worry about back sleeping does not hold. The AAP's Where We Stand page on the Back to Sleep campaign states that there is no evidence that sleeping on the back raises the risk of choking, and that babies who spit up a lot are also placed on their backs. Santé publique France adds that the back position is not the cause of skull deformations: the cause is devices that immobilise an infant, while waking time should happen on a firm mat, in free movement.

The numbers, and what they leave out

The American figures describe a sharp fall and then a plateau. According to the AAP technical report published in 2022 in Pediatrics, the rate of sudden infant death in the United States fell from 120 deaths per 100,000 live births in 1992 to 56 per 100,000 in 2001, a drop of 53 per cent in ten years, then from 54 per 100,000 in 2009 to 33 per 100,000 in 2019. HealthyChildren.org records that since 1992 the annual rate of unexpected infant deaths has fallen by more than 50 per cent.

What parents report and what the numbers ask for do not line up. The PRAMS monitoring for 2016 to 2022 found that 79.8 per cent of mothers said they placed their baby on the back, but only 35.6 per cent reported a firm, compliant sleep surface with the baby alone, and 32.8 per cent reported sleep without loose bedding.

Two limits belong here. The studies behind the recommendation against home monitoring date from 1986 to 2001, and no randomised trial of these devices exists. A reader should hold both ideas at once: the absence of evidence that a monitor prevents a death is not, on its own, proof that monitoring a specific condition cannot help, which is why that judgement belongs to a doctor rather than to a product listing.

When a doctor prescribes one, and the rest of the night

Monitoring a baby at home can be a medical decision. The AAP's level A recommendation concerns monitors used as a general strategy to reduce risk, not the targeted follow-up of a baby whose doctor has decided to watch a particular condition. The FDA states that no device has been authorised to prevent sudden infant death, so the choice of any monitor, and the reason for it, stays with a clinician.

Where the evidence is firm is the sleep itself. Back for every sleep, a firm flat surface, no soft bedding or objects, a room shared without a shared bed, and an adult nearby, are the points the AAP technical report of 2022 and the FDA both point to.

Questions about a baby's breathing, a monitor's readings or a night that felt wrong belong with the paediatrician, the doctor who follows the child, or a health visitor in France's maternal and child protection service, the PMI. Those professionals can say what a device measures, what it does not, and whether monitoring is useful in a given situation. A monitor sold online is not a substitute for that conversation.

Spotted an error in this article? Tell us